Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis.
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024 ERAS stock results show that Erasca missed analyst estimates for earnings per share the second quarter of 2024.
ERAS Stock Earnings: Erasca Misses EPS for Q1 2024 ERAS stock results show that Erasca missed analyst estimates for earnings per share the first quarter of 2024.
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't This oncology biotech, developing targeted cancer therapies, reported a notable insider sale following a remarkable year for its stock.
Erasca (ERAS) Stock Slides After The Bell: Here's Why Erasca Inc (
NASDAQ:ERAS ) shares are moving lower in extended trading Tuesday after the company announced a proposed public offering.
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake.
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (
NASDAQ: RVMD ) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (
NYSE: ABBV ) was in advanced discussions
